<DOC>
	<DOCNO>NCT02151149</DOCNO>
	<brief_summary>Study compare two regimen nab-paclitaxel carboplatin combination elderly subject ( ≥ 70 year old ) advance NSCLC</brief_summary>
	<brief_title>Safety Efficacy Study Abraxane Combination With Carboplatin Treat Advanced NSCL Cancer Elderly</brief_title>
	<detailed_description>This Phase IV , randomize , open-label , multicenter study continuous weekly versus weekly time three one-week break nab-paclitaxel combination carboplatin first-line treatment elderly subject ( ≥ 70 year old ) advance non small cell lung cancer receive prior chemotherapy advance disease candidate curative surgery radiation therapy . The primary study endpoint percentage subject either peripheral neuropathy myelosuppression adverse event . Patients continue treatment develop progressive disease , unacceptable side-effects wish withdraw study , accord local standard care . Patients radiographic evaluation every 6 week treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Large Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Age ≥ 70 year time signing Informed Consent Form . 2 . Understand voluntarily provide write informed consent prior conduct study related assessments/procedures . 3 . Able adhere study visit schedule protocol requirement . 4 . Histologically cytologically confirm locally advanced metastatic Non Small Cell Lung Cancer candidate curative surgery radiation therapy . 5 . No current active malignancy require anticancer therapy . 6 . Radiographically document measurable disease per RECIST v 1.1 7 . No prior chemotherapy treatment metastatic disease . Adjuvant chemotherapy permit provide cytotoxic chemotherapy complete 12 month prior sign ICF without disease recurrence . Patients previously know epidermal growth factor receptor mutation anaplastic lymphoma kinase gene translocation must fail intolerance one treatment epidermal growth factor receptor tyrosine kinase inhibitor anaplastic lymphoma kinase inhibitor therapy , respectively . 8 . Absolute neutrophil count ≥ 1500 cells/cubic millimetre . 9 . Platelets ≥ 100,000 cells/cubic millimetre . 10 . Hemoglobin ≥ 9 grams/decilitre . 11 . Aspartate transaminase/serum glutamic oxaloacetic transaminase/ alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upperlimit normal range ≤ 5.0 × upper limit normal range liver metastasis . 12 . Total bilirubin ≤ 1.5 millilitre/decilitre ( unless know history Gilberts Syndrome ) . 13 . Creatinine clearance &gt; 40 millilitre/minute calculate use CockcroftGault equation ( renal impairment suspect 24 hour urine collection measurement require ) . 14 . Eastern Cooperative Oncology Group performance status 0 1 . 15 . Females ( 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) ( 2 ) naturally postmenopausal least 24 consecutive month ( ie , menses time precede 24 consecutive month ) . 16 . Male subject must : Practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption 6 month follow study drug discontinuation , even undergone successful vasectomy . 1 . Evidence active brain metastasis , include leptomeningeal involvement ( prior evidence brain metastasis permit treated stable therapy ≥ 4 week prior sign Informed consent form . Magnetic Resonance Imaging brain ( Computed Tomography scan w/contrast ) prefer diagnosis . 2 . History leptomeningeal disease . 3 . Only evidence disease non measurable . 4 . Preexisting peripheral neuropathy Grade 2 , 3 , 4 ( per Common Terminology Criteria Adverse Events v4.0 ) . 5 . Subject receive radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start investigational product , and/or ≥ 30 % bone marrow irradiate . Prior radiation therapy target lesion permit clear progression lesion since radiation complete . 6 . Venous thromboembolism within 1 month prior sign Informed consent form . 7 . Current congestive heart failure ( New York Heart Association Class IIIV ) . 8 . History follow within 6 month prior first administration study drug : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant Electrocardiogram abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder . 9 . Subject know infection hepatitis B C , history human immunodeficiency virus infection , subject receive immunosuppressive myelosuppressive medication would opinion investigator , increase risk serious neutropenic complication . 10 . Subject active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy , define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment . 11.History interstitial lung disease , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis . 12 . Treatment investigational product within 28 day prior sign Informed consent form . 13 . History allergy hypersensitivity nabpaclitaxel carboplatin . 14 . Currently enrol clinical protocol investigational trial involve administration experimental therapy and/or therapeutic device . 15 . Any clinically significant medical condition , psychiatric illness , and/or organ dysfunction interfere administration therapy accord protocol , view investigator , preclude combination chemotherapy . 16 . Subject malignancy within 5 year prior randomization . Exceptions include follow : squamous cell carcinoma skin , insitu carcinoma cervix , uteri , nonmelanomatous skin cancer , carcinoma situ breast , incidental histological finding prostate cancer ( TNM stage T1a T1b ) . All treatment complete 6 month prior sign Informed consent form . 17 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 18 . Any medical condition confounds ability interpret data study . 19 . Females ( 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) ( 2 ) naturally postmenopausal least 24 consecutive month ( ie , menses time precede 24 consecutive month ) .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NSCLC advance non-small cell lung cancer squamous adenocarcinoma large cell carcinoma lung cancer elderly first line treatment abraxane carbo nab-paclitaxel</keyword>
</DOC>